Concepedia
Statistics
Publications
12
Citations
2.3K
H-Index
Active since
1998
Affiliations
Exelixis (United States)(Current)
Case Western Reserve University
Gene Therapy Laboratory
University of Tennessee at Knoxville
Sunesis (United States)
Yongchang Shi is an author at Exelixis (United States) specializing in life sciences, pharmacology, and cell signaling.
Publications per year
1998–2023
Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
F. Michael Yakes, Jason Chen, Jenny Tan et al. · Molecular Cancer Therapeutics · 2011 · 1.3K citations · Full text
Medicine, Oncology, Pharmacology +17
Blockade of the Phagocytic Receptor MerTK on Tumor-Associated Macrophages Enhances P2X7R-Dependent STING Activation by Tumor-Derived cGAMP
Yi Zhou, Mingjian Fei, Gu Zhang et al. · Immunity · 2020 · 402 citations · Full text
Life Sciences, Immunology, Pharmacology +14
<i>In Vitro</i> and <i>In Vivo</i> Activity of Cabozantinib (XL184), an Inhibitor of RET, MET, and VEGFR2, in a Model of Medullary Thyroid Cancer
Frauke Bentzien, Marcus Zuzow, Nathan Heald et al. · Thyroid · 2013 · 130 citations · Full text
Medicine, Oncology, Pharmacology +16
Inhibition of the T790M Gatekeeper Mutant of the Epidermal Growth Factor Receptor by EXEL-7647
Steven Gendreau, Richard Ventura, Paul Keast et al. · Clinical Cancer Research · 2007 · 89 citations
Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic–Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor
Harvey Wong, Laurent Vernillet, Amy Peterson et al. · Clinical Cancer Research · 2012 · 79 citations
Pharmacy, Pharmacokinetics, Pharmacology +17
1–5 of 12